Featured Research

from universities, journals, and other organizations

Nonsteroidal anti-inflammatory agent slows rate of progression of neurodegenerative disease

Date:
December 24, 2013
Source:
The JAMA Network Journals
Summary:
Among patients with familial amyloid polyneuropathy, a lethal, genetic neurodegenerative disease, use of the nonsteroidal anti-inflammatory agent diflunisal compared with placebo for two years reduced the rate of progression in neurological impairment and preserved quality of life, according to a study.

Among patients with familial amyloid polyneuropathy, a lethal, genetic neurodegenerative disease, use of the nonsteroidal anti-inflammatory agent diflunisal compared with placebo for 2 years reduced the rate of progression in neurological impairment and preserved quality of life, according to a study appearing in the December 25 issue of JAMA.

Related Articles


Familial amyloid polyneuropathy is characterized by progressive neurologic deficits and disability which prove fatal if left untreated. Fewer than 10,000 people are estimated to be clinically affected worldwide, according to background information in the article. Diflunisal showed potential benefit in a phase 1 study.

John L. Berk, M.D., of the Boston University School of Medicine, and colleagues, pursuing the NIH mission to repurpose old drugs, randomized 130 patients from Sweden, Italy, Japan, England, and the United States to receive diflunisal (n=64) or placebo (n=66) twice daily for 2 years to determine the effect of diflunisal on polyneuropathy progression in patients with familial amyloid polyneuropathy.

Patients randomized to diflunisal exhibited less progression of polyneuropathy than those assigned to placebo. The inhibitory effect of diflunisal on neuropathy progression was detectable at 1 and 2 years, and at 2 years, 29.7 percent of the diflunisal group compared to 9.4 percent of the placebo group exhibited neurological stability. Physical quality of life stabilized from the beginning of the study to 2 years in those assigned to diflunisal treatment while decreasing in the placebo group.

The authors write that their trial is pivotal for several reasons: it is the first randomized trial involving a broad cross-section of the spectrum of disease; it provides invaluable natural history data on the rate of neurological disease progression; and it establishes that diflunisal, a low-cost treatment, is well tolerated by familial amyloid polyneuropathy patients with a spectrum of neuropathy.

"Although longer-term follow-up studies are needed, these findings suggest benefit of this treatment for familial amyloid polyneuropathy."


Story Source:

The above story is based on materials provided by The JAMA Network Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. John L. Berk, MD; Ole B. Suhr, MD, PhD; Laura Obici, MD; Yoshiki Sekijima, MD, PhD; Steven R. Zeldenrust, MD, PhD; Taro Yamashita, MD, PhD; Michael A. Heneghan, MD; Peter D. Gorevic, MD; William J. Litchy, MD; Janice F. Wiesman, MD; Erik Nordh, MD, PhD; Manuel Corato, MD, PhD; Alessandro Lozza, MD; Andrea Cortese, MD; Jessica Robinson-Papp, MD; Theodore Colton, ScD; Denis V. Rybin, MS; Alice B. Bisbee, MPH; Yukio Ando, MD, PhD; Shu-ichi Ikeda, MD, PhD; David C. Seldin, MD, PhD; Giampaolo Merlini, MD; Martha Skinner, MD; Jeffery W. Kelly, PhD; Peter J. Dyck, MD. Repurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial PDF. JAMA, December 2013

Cite This Page:

The JAMA Network Journals. "Nonsteroidal anti-inflammatory agent slows rate of progression of neurodegenerative disease." ScienceDaily. ScienceDaily, 24 December 2013. <www.sciencedaily.com/releases/2013/12/131224183630.htm>.
The JAMA Network Journals. (2013, December 24). Nonsteroidal anti-inflammatory agent slows rate of progression of neurodegenerative disease. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2013/12/131224183630.htm
The JAMA Network Journals. "Nonsteroidal anti-inflammatory agent slows rate of progression of neurodegenerative disease." ScienceDaily. www.sciencedaily.com/releases/2013/12/131224183630.htm (accessed October 25, 2014).

Share This



More Mind & Brain News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Academic Scandal Shocks UNC

Academic Scandal Shocks UNC

AP (Oct. 23, 2014) A scandal involving bogus classes and inflated grades at the University of North Carolina was bigger than previously reported, a new investigation found. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Working Mother Getaway: Beaches Turks & Caicos

Working Mother Getaway: Beaches Turks & Caicos

Working Mother (Oct. 22, 2014) Feast your eyes on this gorgeous family-friendly resort. Video provided by Working Mother
Powered by NewsLook.com
What Your Favorite Color Says About You

What Your Favorite Color Says About You

Buzz60 (Oct. 22, 2014) We all have one color we love to wear, and believe it or not, your color preference may reveal some of your character traits. In celebration of National Color Day, Krystin Goodwin (@kyrstingoodwin) highlights what your favorite colors may say about you. Video provided by Buzz60
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins